This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): HOE140, icatibant
Description: Icatibant is a synthetic decapeptide antagonist directed against the bradykinin type-2 receptor. Bradykinin is a peptide hormone that is formed locally in the body, very often as a response to trauma. Bradykinin increases vascular permeability, dilates blood vessels, contracts non-vascular smooth muscle cells, and is a powerful mediator of pain. Excessive levels of bradykinin cause typical symptoms of inflammation, including swelling, reddening, warmth, and pain. These effects are mediated through the bradykinin B2 receptors.
Icatibant is structurally similar to bradykinin with the exception of 5 nonproteinogenicamino acids. It is supplied as a single-use, pre-filled 25-gauge syringe containing 30 mg icatibant acetate in 3 mL solution.
Jerini and Sanofi
In 2001, Jerini licensed Icatibant from Sanofi-Aventis and is obligated to pay royalties of 12% of worldwide revenues. Jerini is also obligated to pay EU 7 million on filing the NDA and obtaining marketing approval. In addition, it may need to pay 20% of payments from sublicensees that are not for NDA filing or obtaining marketing approval.
Jerini, Abbott and Kos
On November 7, 2005, Kos Life Sciences, a subsidiary of Kos Pharmaceuticals and Jerini US, a subsidiary of Jerini AG,announced the signing of an exclusive agreement for the development, marketing and distribution of Jerini's compound, Icatibant, in the United States and Canada. The strategic partnershipincludes an upfront licensing payment of EUR 12 million (approx.$15 million), along with a EUR 10 million (approx.$12 million) equity investment out of a capital increase at the higher of the weighted average of the closing price of Jerini's shares during the last four trading days, or...See full deal structure in Biomedtracker
Additional information available to subscribers only: